We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0Y5E market cap is 10.26B. The company's latest EPS is USD -0.0937 and P/E is -257.52.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.84B | 5.07B | 4.56B | 4.45B | 4.66B |
| Operating Income | 207.5M | 112.4M | 566.5M | 78.9M | 151.9M |
| Net Income | 146.1M | -162.6M | -68.9M | -140.6M | -12.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 11.3B | 11.49B | 10.43B | 11.02B | 10.81B |
| Total Liabilities | 5.5B | 5.83B | 5.27B | 6.18B | 6.04B |
| Total Equity | 5.8B | 5.66B | 5.15B | 4.84B | 4.77B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 387.8M | 636.2M | 156.3M | 307.3M | 405.5M |
| Investing | -596.1M | -187.8M | 1.28B | -1.96B | -77.5M |
| Financing | 1.8M | -181.1M | -178.7M | 421.6M | -187.2M |
| Market Cap | 10.26B |
| Price to Earnings Ratio | -257.52 |
| Price to Sales Ratio | 0.7 |
| Price to Cash Ratio | 4.39 |
| Price to Book Ratio | 0.69 |
| Dividend Yield | - |
| Shares Outstanding | 135.51M |
| Average Volume (1 week) | 518 |
| Average Volume (1 Month) | 391 |
| 52 Week Change | 0.00% |
| 52 Week High | 75.69 |
| 52 Week Low | 75.69 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Perrigo Company Plc |
| Address |
the sharp building dublin D02 TY74 |
| Website | https://www.perrigo.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
